Exagen, Inc. Hits New 52-Week High of $11.75, Up 479.9% Year-Over-Year

Exagen, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 11.75 on October 14, 2025. This achievement marks a remarkable increase in the stock's performance, with a staggering 479.9% rise over the past year, significantly outpacing the S&P 500's performance of 14.44% during the same period.
With a market capitalization of USD 216 million, Exagen operates in a competitive industry characterized by innovation and rapid advancements. Despite its recent stock performance, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and return on equity of -77.24%. The stock's price-to-book ratio stands at 10.26, indicating a premium valuation relative to its book value.

As Exagen continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, its recent price movement underscores the volatility and potential within this sector. The stock's journey from a 52-week low of USD 2.38 to its current high illustrates the significant fluctuations that can occur in microcap stocks.